Loading...
Current interferon-free regimens are highly effective in the treatment of hepatitis C virus (HCV) genotype 1 infection, but other HCV genotypes still require treatment with ribavirin, which can cause problematic cases of anemia, pruritus, and insomnia in certain patients.
In an ongoing industry-funded phase IIb study of a once-daily combination pill of ombitasvir, paritaprevir, and ritonavir (currently FDA-approved for use with dasabuvir, ribavirin, or both for HCV genotype 1a or 1b infection) with or without ribavirin in patients with HCV genotype 1b or 4 infection, researchers assessed sustained virologic response 12 weeks after the end of treatment (SVR12) in several subgroups. These included 82 patients without cirrhosis (42 treatment-na…